Web Analytics

3 Latest Announced Rounds

  • $3,500,000
    Seed

    1 Investors

    Technology, Information and Internet
    Dec 20th, 2024
  • $5,619,170
    Series B

    1 Investors

    Research Services
    Dec 20th, 2024
  • $8,000,000
    Unknown

    5 Investors

    Computer & Network Security
    Dec 20th, 2024
$671.88M Raised in 44 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Elligo Health Research

start up
United States - Austin, Texas
  • 03/10/2023
  • Unknown
  • $40,000,000

Elligo Health Research accelerates clinical trials through EHR data, our proprietary IntElligo® technology, and direct access to known, diverse patients from more than 115 hospitals and major health systems, 200 healthcare-based sites, and 100 research-based sites. Our PatientSelect® model engages our network of networks to optimize the intersection of healthcare and research and bring more patients clinical research as a care option. Our SiteSelect model and Research Partner Services enable sites to seamlessly participate in trials, further advancing the development of new pharmaceutical, biotechnology, and medical device and diagnostic products.


Related People

John PotthoffFounder

John Potthoff United States - Austin, Texas Metropolitan Area

For more than 30 years, I’ve focused on helping development service companies excel in the drug/device development industry.

In March 2016, I co-founded and serve as CEO of Elligo Health Research, a company focused on enabling patients and clinicians to participate in clinical trials by providing the needed infrastructure not found at all clinical settings.

From 2011 to 2015, I led Theorem Clinical Research as president and CEO, overseeing the company’s strategy, operational execution and customer experience. In September 2015, after record growth, I led the successful sale of Theorem to Chiltern yielding a record ROI for investors.

Prior to joining Theorem, I served as COO at INC Research. While at INC Research, I helped the company achieve record year-over-year profit by upholding a 40 percent CAGR in sales and revenue for several years. Throughout my career, I oversaw multiple acquisitions, providing the operational guidance for the integration of seven major acquisitions in six years. I played a key role in negotiating the successful sale of INC Research in 2010.